Should I buy or sell Akebia Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AKBA shares. View AKBA analyst ratings or view top-rated stocks .

What is Akebia Therapeutics' stock price target for 2024?

3 Wall Street analysts have issued 12 month target prices for Akebia Therapeutics' shares. Their AKBA share price targets range from $4.00 to $6.00. On average, they anticipate the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 259.7% from the stock's current price. View analysts price targets for AKBA or view top-rated stocks among Wall Street analysts .

How have AKBA shares performed in 2024?

Akebia Therapeutics' stock was trading at $1.24 at the start of the year. Since then, AKBA stock has increased by 12.1% and is now trading at $1.39. View the best growth stocks for 2024 here .

Are investors shorting Akebia Therapeutics?

Akebia Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 13,400,000 shares, an increase of 32.3% from the March 15th total of 10,130,000 shares. Based on an average trading volume of 4,530,000 shares, the days-to-cover ratio is currently 3.0 days. View Akebia Therapeutics' Short Interest .

When is Akebia Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our AKBA earnings forecast .

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics, Inc. (NASDAQ:AKBA) posted its quarterly earnings data on Thursday, March, 14th. The biopharmaceutical company reported ($0.04) EPS for the quarter, meeting the consensus estimate of ($0.04). The biopharmaceutical company had revenue of $56.20 million for the quarter, compared to analyst estimates of $55.64 million. During the same quarter last year, the firm earned ($0.04) earnings per share.

What is John Butler's approval rating as Akebia Therapeutics' CEO?

28 employees have rated Akebia Therapeutics Chief Executive Officer John Butler on Glassdoor.com . John Butler has an approval rating of 97% among the company's employees. This puts John Butler in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Akebia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX) , Gilead Sciences (GILD) , AbbVie (ABBV) , Energy Transfer (ET) , Micron Technology (MU) , TherapeuticsMD (TXMD) , Corbus Pharmaceuticals (CRBP) , Pfizer (PFE) , NVIDIA (NVDA) and AT&T (T) .

How do I buy shares of Akebia Therapeutics?

Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:AKBA

Akebia Therapeutics (AKBA) Stock Price, News & Analysis

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

Free AKBA Stock Alerts

$1.39

-0.07 (-4.79%)

(As of 04/15/2024 ET)

Compare

Today's Range: $1.39
▼
$1.45
50-Day Range: $1.35
▼
$2.24
52-Week Range: $0.59
▼
$2.48

Volume: 3.88 million shs
Average Volume: 4.45 million shs
Market Capitalization: $291.02 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

Get Akebia Therapeutics alerts:

Akebia Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 259.7% Upside
$5.00 Price Target
Short Interest: Bearish
6.40% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.35
Upright™ Environmental Score
News Sentiment: 0.65
Based on 6 Articles This Week
Insider Trading: Selling Shares
$300,598 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.28) to ($0.19) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.77 out of 5 stars

Medical Sector

227th out of 929 stocks

Pharmaceutical Preparations Industry

91st out of 422 stocks

3.5

Analyst's Opinion

Consensus Rating
Akebia Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Akebia Therapeutics has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
6.40% of the outstanding shares of Akebia Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Akebia Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Akebia Therapeutics has recently increased by 32.28%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Akebia Therapeutics does not currently pay a dividend.
Dividend Growth
Akebia Therapeutics does not have a long track record of dividend growth.

4.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Akebia Therapeutics has received a 55.61% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Various other types of medication (V)" and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Akebia Therapeutics is -1.35.

3.1

News and Social Media Coverage

News Sentiment
Akebia Therapeutics has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Akebia Therapeutics this week, compared to 3 articles on an average week.
Search Interest
67 people have searched for AKBA on MarketBeat in the last 30 days. This is an increase of 644% compared to the previous 30 days.
MarketBeat Follows
59 people have added Akebia Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 556% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Akebia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $300,598.00 in company stock.
Percentage Held by Insiders
Only 3.84% of the stock of Akebia Therapeutics is held by insiders.
Percentage Held by Institutions
Only 33.92% of the stock of Akebia Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Akebia Therapeutics are expected to grow in the coming year, from ($0.28) to ($0.19) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Akebia Therapeutics is -4.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Akebia Therapeutics is -4.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

>>Check out what this A.I. Perfect Storm is<<

About Akebia Therapeutics Stock (NASDAQ:AKBA)

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

AKBA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AKBA Stock News Headlines

April 3, 2024 | marketbeat.com

Akebia Therapeutics Surges on FDA Approval for Anemia Treatment

Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia

April 3, 2024 | marketbeat.com

Akebia Therapeutics Surges on FDA Approval for Anemia Treatment

Akebia Therapeutics Inc. NASDAQ: AKBA is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia management for patients with CKD. The medical sector company addresses unmet needs in the segment.

April 16, 2024 | Crypto Swap Profits (Ad)

Did You Get Your Free Bitcoin Yet?

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

April 15, 2024 | americanbankingnews.com

Short Interest in Akebia Therapeutics, Inc. (NASDAQ:AKBA) Grows By 32.3%

April 11, 2024 | americanbankingnews.com

Akebia Therapeutics (NASDAQ:AKBA) Cut to Hold at StockNews.com

March 29, 2024 | msn.com

Biggest stock movers today: AMC, PLTR, RH, and more

March 28, 2024 | finance.yahoo.com

FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia

March 28, 2024 | msn.com

Akebia stock jumps as FDA clears renal anemia therapy

April 16, 2024 | Crypto Swap Profits (Ad)

Did You Get Your Free Bitcoin Yet?

March 28, 2024 | markets.businessinsider.com

Akebia's Vafseo Tablets Approved By FDA For Anemia Treatment In Dialysis Patients

March 28, 2024 | bizjournals.com

Two years after initial rejection, Akebia’s anemia drug finally gets FDA approval

March 27, 2024 | reuters.com

U.S. FDA approves Akebia's anemia drug

March 27, 2024 | prnewswire.com

Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis

March 27, 2024 | finance.yahoo.com

Akebia Awaits FDA Word On Second Crack At Vadadustat

March 17, 2024 | finance.yahoo.com

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.33

March 16, 2024 | finance.yahoo.com

Akebia Therapeutics Full Year 2023 Earnings: EPS Beats Expectations

March 15, 2024 | markets.businessinsider.com

Buy Rating for Akebia Therapeutics Amid Anticipated Approval of Anemia Drug Vadadustat and Strong Financial Position

March 15, 2024 | finance.yahoo.com

US Life & Non-Life Insurance Market Poised for Strong Growth: In-Depth Analysis Unveiled

March 14, 2024 | investorplace.com

AKBA Stock Earnings: Akebia Therapeutics Beats Revenue for Q4 2023

March 14, 2024 | benzinga.com

Recap: Akebia Therapeutics Q4 Earnings

March 14, 2024 | finance.yahoo.com

Akebia Therapeutics Inc (AKBA) Reports Steady Revenue and a Profitable Quarter

March 14, 2024 | prnewswire.com

Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

March 14, 2024 | markets.businessinsider.com

Akebia Therapeutics earnings: here's what Wall Street expects

March 13, 2024 | benzinga.com

Earnings Preview For Akebia Therapeutics

March 11, 2024 | finance.yahoo.com

Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

March 11, 2024 | prnewswire.com

Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

March 1, 2024 | prnewswire.com

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

See More Headlines

Receive AKBA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/14/2024
Today: 4/15/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:AKBA
CUSIP: N/A
CIK: 1517022
Web: www.akebia.com
Phone: (617) 871-2098
Fax: 617-871-2099
Employees: 167
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.00
High Stock Price Target: $6.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +255.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.28)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-51,920,000.00
Net Margins: -26.32%
Pretax Margin: -26.68%
Return on Equity: N/A
Return on Assets: -20.36%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.18
Quick Ratio: 1.03

Sales & Book Value

Annual Sales: $194.62 million
Price / Sales: 1.51
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.16) per share
Price / Book: -8.78

Miscellaneous

Outstanding Shares: 209,370,000
Free Float: 201,332,000
Market Cap: $294.16 million
Optionable: Optionable
Beta: 0.79

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. John P. Butler MBA (Age 60)
CEO, President, Interim Principal Financial Officer & Director
Comp: $1.29M
Mr. Michel Dahan (Age 45)
Senior VP & COO
Comp: $734.73k
Ms. Nicole R. Hadas J.D. (Age 51)
Senior VP, Chief Legal Officer & Secretary
Comp: $687.38k
Dr. Steven Keith Burke M.D. (Age 63)
Senior VP of Research & Development and Chief Medical Officer
Comp: $766.57k
Mr. Richard C. Malabre (Age 63)
Chief Accounting Officer
Ms. Kimberly Garko
Senior VP & Chief Technical Officer
Tracey Vetterick
Vice President of Portfolio Strategy & Corporate Administration
Mercedes Carrasco
Director of Corporate Communications
Ms. Meredith Bowman
Senior VP & Chief People Officer
Ms. Carolyn Rucci
Senior Vice President of Legal & General Counsel

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AKBA Stock Analysis - Frequently Asked Questions

Should I buy or sell Akebia Therapeutics stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AKBA shares.
View AKBA analyst ratings or view top-rated stocks.
What is Akebia Therapeutics' stock price target for 2024?: 3 Wall Street analysts have issued 12 month target prices for Akebia Therapeutics' shares. Their AKBA share price targets range from $4.00 to $6.00. On average, they anticipate the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 259.7% from the stock's current price.
View analysts price targets for AKBA or view top-rated stocks among Wall Street analysts.
How have AKBA shares performed in 2024?: Akebia Therapeutics' stock was trading at $1.24 at the start of the year. Since then, AKBA stock has increased by 12.1% and is now trading at $1.39.
View the best growth stocks for 2024 here.
Are investors shorting Akebia Therapeutics?: Akebia Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 13,400,000 shares, an increase of 32.3% from the March 15th total of 10,130,000 shares. Based on an average trading volume of 4,530,000 shares, the days-to-cover ratio is currently 3.0 days.
View Akebia Therapeutics' Short Interest.
When is Akebia Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our AKBA earnings forecast.

How were Akebia Therapeutics' earnings last quarter?: Akebia Therapeutics, Inc. (NASDAQ:AKBA) posted its quarterly earnings data on Thursday, March, 14th. The biopharmaceutical company reported ($0.04) EPS for the quarter, meeting the consensus estimate of ($0.04). The biopharmaceutical company had revenue of $56.20 million for the quarter, compared to analyst estimates of $55.64 million. During the same quarter last year, the firm earned ($0.04) earnings per share.
What is John Butler's approval rating as Akebia Therapeutics' CEO?: 28 employees have rated Akebia Therapeutics Chief Executive Officer John Butler on Glassdoor.com. John Butler has an approval rating of 97% among the company's employees. This puts John Butler in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Akebia Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T).
How do I buy shares of Akebia Therapeutics?: Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AKBA) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial